Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy ... (al effectagainst both genotype 1a and 1b...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

Date:11/1/2008

al effect against both genotype 1a and 1b. In two HCV genotype 1b animals dosed over four days, maximum viral load reductions of 2.2 and 2.6 log10 were observed within 24 to 48 hours after the initial dose. In one animal the viral load reduction was sustained throughout the remaining dosing period, while in the second animal a modest rise in viral load was seen over days three and four. In two HCV genotype 1a animals that each received a single dose of ANA598, viral load reductions of 0.5 and 1.4 log10 were seen at 48 hours post-dose.

About ANA598

Anadys recently initiated patient dosing in a Phase Ib study of ANA598 in HCV patients. Naive genotype 1a and 1b patients will receive ANA598 over three days at doses of 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid. Ten patients will be enrolled at each dose level, eight receiving active drug and two receiving placebo. Anadys recently completed dosing in the Phase I study of ANA598 in healthy volunteers.

Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In the preclinical program, ANA598 was well tolerated at all doses tested in 28-day GLP toxicology studies. In September, Anadys initiated long-term chronic toxicology studies of ANA598. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of these and other non-clinical activities into 2008 will enable a more rapid and continuous development path into Phase II studies during 2009.

Clinical Need and Market Opportunity in HCV Infection

Chronic HCV infection is a serious public health concern affecting approximately 3.2 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the live
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415

Post Your Comments:

Breaking Medicine Technology:Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 2 Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 3 Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2 Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3 BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 2 BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 3 Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 1 Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 2 Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 3 Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 4 Study highlights from November issue of GIE 3A Gastrointestinal Endoscopy 61945 1 Study highlights from November issue of GIE 3A Gastrointestinal Endoscopy 61945 2 Study highlights from November issue of GIE 3A Gastrointestinal Endoscopy 61945 3 Study highlights from November issue of GIE 3A Gastrointestinal Endoscopy 61945 4 Study highlights from November issue of GIE 3A Gastrointestinal Endoscopy 61945 5 Upending textbook science on Alzheimers disease 61940 1 Upending textbook science on Alzheimers disease 61940 2

[0] Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities [0] Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology [0] BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog

Other Medicine Technology:Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists 2 Shingles Pain Treatment Will Benefit More Patients 2 Shingles Pain Treatment Will Benefit More Patients 3 Shingles Pain Treatment Will Benefit More Patients 4

Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists Shingles Pain Treatment Will Benefit More Patients

[0] Soy Beneficial for Breast Cancer Survivors: Study [1] Researchers Use New Techniques to Assess PTSD [0] Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)[1] Patient Safety Organization (PSO) Participation: What Every Provider Needs to Know [1] Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends)

Other Medicine News:Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 2 Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 3 Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 4 Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 5 Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 6 Health News:Sun Pharmaceutical Extends Tender Offer for Taro 2 Health News:Sun Pharmaceutical Extends Tender Offer for Taro 3 Health News:Researchers Suspect Genetic Link to COPD 2 Health News:Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status 2 Health News:Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status 3 Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 2 Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 3 Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 4 Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 5 Health News:New initiative to support pediatric migraine research is announced 2

Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents Sun Pharmaceutical Extends Tender Offer for Taro Researchers Suspect Genetic Link to COPD Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems New initiative to support pediatric migraine research is announced

Medicine Products:

Poliovirus Culture PM-Scl Antibody, ID Platelet Antigen Genotyping Panel Platelet Antigen 4 Genotyping (HPA-4)

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy ...(al effectagainst both genotype 1a and 1b...),Health